Skip to main content
SpringerLink
Log in

Heparin After Acute Myocardial Infarction

  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

Heparin is commonly, but by no means universally, used after acute myocardial infarction. When used the dose, route of administration, and duration of therapy varies considerably. The role of heparin is reviewed with particular reference to its use in conjunction with other commonly used therapies, such as aspirin and thrombolytic agents. Intravenous heparin after thrombolytic therapy remains untested in patients treated with aspirin. When used, benefit is seen in a narrow aPTT range, and there have been unexpected increases in mortality in patients with the greatest heparin effect. The addition of delayed subcutaneous heparin to aspirin and thrombolytic therapy does not provide a mortality benefit. In patients not treated with thrombolysis, there is no clear evidence that heparin confers significant mortality benefit if patients are treated with aspirin. Heparin therapy may reduce the incidence of intraventricular thrombus after anterior wall infarction, but there is no clear evidence that it reduces the clinically important sequelae of cerebral embolism and stroke. Given concerns about increased hemorrhagic rates with heparin and unknown benefit, it is reasonable to conclude that its role in the management of patients with acute myocardial infarction remains unclear.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Davies MJ, Thomas AC. Plaque fissuring—the cause of acute myocardial infarction, sudden ischaemic death and crescendo angina. Br Heart J 1985;53:363–373.

    Google Scholar 

  2. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:242–50:310–318.

    Google Scholar 

  3. Cerebral Embolism Task Force. Cardiogenic brain embolism. The second report of the Cerebral Embolism Task Force. Arch Neurol 1989;46:727–743.

    Google Scholar 

  4. Guidelines for the early management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on assessment of diagnostic and therapeutic cardiovascular procedures (Sub-Committee to Develop Guidelines for the Early Management of Patients with Acute Myocardial Infarction). J Am Coll Cardiol 1990;16:249–292.

  5. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 1988;2:349–360.

    Google Scholar 

  6. O'Donnell CJ, Ridker PM, Hebert PR, Hennekens CH. Antithrombotic therapy for acute myocardial infarction. J Am Coll Cardiol 1995;25(Suppl):23S–29S.

    Google Scholar 

  7. Ridker PM, Hebert PR, Fuster V, Hennekens CH. Are both aspirin and heparin justified as adjuncts to thrombolytic therapy for acute myocardial infarction? Lancet 1993;341:1574–1577.

    Google Scholar 

  8. McMurray J, Rankin A. Cardiology-I. Treatment of myocardial infarction, unstable angina and angina pectoris. Br Med J 1994;309:1343–1350.

    Google Scholar 

  9. Rogers WJ, Bowlby LJ, Chandra NC, et al. for the Participants in the National Registry of Myocardial Infarction. Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial Infarction. Circulation 1994;90:2103–2114.

    Google Scholar 

  10. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1,000 patients. Lancet 1994;343:311–322.

    Google Scholar 

  11. Verheught FWA, Meijer A, Lagrand WK, van Enige MJ. Reocclusion: The flip side of coronary thrombolysis. J Am Coll Cardiol 1996;27:766–773.

    Google Scholar 

  12. Ohman EM, Califf RM, Topol EJ, et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 1990;82:781–791.

    Google Scholar 

  13. Fitzgerald DJ, Catella F, Roy L, Fitzgerald GA. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 1988;77:142–150.

    Google Scholar 

  14. Aronson DL, Chang P, Kessler CM. Platelet-dependent thrombi generation after in vitro fibrinolytic treatment. Circulation 1992;85:1706–1712.

    Google Scholar 

  15. Gash AK, Spann JF, Sherky S, et al. Factors influencing reocclusion after coronary thrombolysis for acute myocardial infarction. Am J Cardiol 1986;57:175–177.

    Google Scholar 

  16. Inoue K, Ochiai H, Kuwaki K. The mechanism of reocclusion after successful coronary thrombolysis as validated by percutaneous angioscopy (abstract). J Am Coll Cardiol 1994;23:13A.

    Google Scholar 

  17. Mahaffey KW, Granger CB, Collins R, et al. Overview of randomised trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. Am J Cardiol 1996;77:551–556.

    Google Scholar 

  18. Hsia J, Kleiman NS, Aguirre FV, Chaitman BR, Roberts R, Ross AM. Heparin-induced prolongation of partial thromboplastin time after thrombolysis: Relation to coronary artery patency. J Am Coll Cardiol 1992;20:31–35.

    Google Scholar 

  19. Arnout J, Simoons M, de Bono D, Rapold HJ, Collen D, Verstraete M. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA). J Am Coll Cardiol 1992;20:513–519.

    Google Scholar 

  20. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615–1622.

    Google Scholar 

  21. Granger CB, Hirsh J, Califf RM, et al. for the GUSTO-I Investigators. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction. Results from the GUSTO-I Trial. Circulation 1996;93:870–878.

    Google Scholar 

  22. Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992;327:141–145.

    Google Scholar 

  23. Di Tano G, Mazzu A. Early reactivation of ischaemia after abrupt discontinuation of heparin in acute myocardial infarction. Br Heart J 1995;74:131–133.

    Google Scholar 

  24. Antman EM for the TIMI 9B Investigators. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 1996;94:911–921.

    Google Scholar 

  25. Gruppo Italiano per lo Studio della Sopravivenza Nell' Infarto Miocardico. GISSI-2: A factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336:65–71.

    Google Scholar 

  26. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: A randomized comparison of streptokinase versus tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:753–770.

    Google Scholar 

  27. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673–682.

    Google Scholar 

  28. The Global Use of Strategies To Open Occluded Coronary Arteries (GUSTO) IIa INvestigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994;90:1631–1637.

    Google Scholar 

  29. Antman EM, for the TIMI 9a Investigators. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9a trial. Circulation 1994;90:1624–1630.

    Google Scholar 

  30. MacMahon S, Collins R, Knight C, Yusuf S, Peto R. Reduction in major morbidity and mortality by heparin in acute myocardial infarction (abstract). Circulation 1988;78(Suppl II):II93.

    Google Scholar 

  31. Assessment of short-term anticoagulant administration after cardiac infarction. Report of the Working Party on Anticoagulant Therapy in Coronary Thrombosis to the Medical Research Council. Br Med J 1981;1:335–342.

    Google Scholar 

  32. Anticoagulants in acute myocardial infarction. Results of a co-operative clinical trial. JAMA 1973;225:724–30.

  33. Drapkin A, Merskey C. Anticoagulant therapy after acute myocardial infarction. Relation of therapeutic benefit to patients age, sex and severity of infarction. JAMA 1972;222:541–548.

    Google Scholar 

  34. McGovern PG, Pankow JS, Shahar E, et al. for the Minnesota Heart Survey Investigators. Recent trends in acute coronary heart disease. Mortality, morbidity, medical care and risk factors. N Engl J Med 1996;334:884–890.

    Google Scholar 

  35. LATE Study Group. Late assessment of thrombolytic efficacy (LATE) study with alteplase 6–24 hours after onset of acute myocardial infarction. Lancet 1993;342:759–766.

    Google Scholar 

  36. Fuster V, Halperin JL. Left ventricular thrombi and cerebral embolism. N Engl J Med 1989;320:392–393.

    Google Scholar 

  37. Vaitkus PT, Berlin JA, Schwartz JS, Barnathan ES. Stroke complicating acute myocardial infarction. A meta-analysis of risk modification by anticoagulation and thrombolytic therapy. Arch Intern Med 1992;152:2020–2024.

    Google Scholar 

  38. Turpie AGG, Robinson JG, Doyle DJ, et al. Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med 1989;320:352–357.

    Google Scholar 

  39. Bodenheimer MM, Sauer D, Shareef B, Brown MW, Fleiss JL, Moss AJ. Relation between myocardial infarct location and stroke. J Am Coll Cardiol 1994;24:61–66.

    Google Scholar 

  40. Nihoyannopoulos P, Smith GC, Maseri A, Foale RA. The natural history of left ventricular thrombus in myocardial infarction: A rationale in support of masterly inactivity. J Am Coll Cardiol 1989;14:903–911.

    Google Scholar 

  41. Halperin JL, Fuster V. Left ventricular thrombus and stroke after myocardial infarction: Toward prevention or perplexity? J Am Coll Cardiol 1989;14:912–914.

    Google Scholar 

  42. Loscalzo J. Thrombin inhibitors in fibrinolysis. A Hobson's choice of alternatives. Circulation 1996;94:863–865.

    Google Scholar 

  43. Collins R, MacMahon S, Flather M, et al. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. Br Med J 1996;313:652–659.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiac Clinic, Department of Medicine, Groote Schuur Hospital and the, University of Cape Town, Cape Town, South Africa

    Patrick Joseph Commerford

Authors
  1. Patrick Joseph Commerford
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Commerford, P.J. Heparin After Acute Myocardial Infarction. Cardiovasc Drugs Ther 11, 101–109 (1997). https://doi.org/10.1023/A:1007724628936

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1007724628936

Search

Navigation